EP2020850A4 - Nouveaux cannabinoïdes et procédés d'utilisation - Google Patents

Nouveaux cannabinoïdes et procédés d'utilisation

Info

Publication number
EP2020850A4
EP2020850A4 EP07794433A EP07794433A EP2020850A4 EP 2020850 A4 EP2020850 A4 EP 2020850A4 EP 07794433 A EP07794433 A EP 07794433A EP 07794433 A EP07794433 A EP 07794433A EP 2020850 A4 EP2020850 A4 EP 2020850A4
Authority
EP
European Patent Office
Prior art keywords
methods
novel cannabinoids
cannabinoids
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07794433A
Other languages
German (de)
English (en)
Other versions
EP2020850A1 (fr
Inventor
Patricia B Williams
Billy R Martin
Frank A Lattanzio
Sandeep Samudre
Raj K Razdan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Publication of EP2020850A1 publication Critical patent/EP2020850A1/fr
Publication of EP2020850A4 publication Critical patent/EP2020850A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07794433A 2006-05-01 2007-05-01 Nouveaux cannabinoïdes et procédés d'utilisation Withdrawn EP2020850A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79614306P 2006-05-01 2006-05-01
PCT/US2007/010474 WO2007130361A1 (fr) 2006-05-01 2007-05-01 Nouveaux cannabinoïdes et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2020850A1 EP2020850A1 (fr) 2009-02-11
EP2020850A4 true EP2020850A4 (fr) 2010-10-13

Family

ID=38668080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07794433A Withdrawn EP2020850A4 (fr) 2006-05-01 2007-05-01 Nouveaux cannabinoïdes et procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP2020850A4 (fr)
JP (1) JP2009538827A (fr)
CN (1) CN101484004A (fr)
AU (1) AU2007248760A1 (fr)
CA (1) CA2650900A1 (fr)
WO (1) WO2007130361A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341903A1 (fr) * 2008-07-31 2011-07-13 Bionorica Research GmbH Cannabinoïdes destinés à une utilisation dans le traitement ou la prévention des troubles cognitifs et de la démence
US12023332B2 (en) 2018-03-05 2024-07-02 Wylder Nation Foundation Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
EP3773651A4 (fr) * 2018-04-04 2022-02-16 Eye Co Pty Ltd. Extrait de chanvre contenant une faible quantité de thc et méthode de traitement ou de prévention d'une maladie oculaire
IL271681A (en) 2018-07-18 2020-01-30 Vyripharm Entpr Llc Systems and methods for integrated and comprehensive management of cannabis products
EP3997084A4 (fr) * 2019-07-12 2023-06-07 Canopy Growth Corporation Dérivés cannabinoïdes
WO2021236890A1 (fr) * 2020-05-20 2021-11-25 Wylder Nation Foundation Compositions et procédés pour activer une signalisation par l'intermédiaire du récepteur cannabinoïde cb2 pour traiter et prévenir des troubles et des maladies du déficit du stockage lysosomal
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
WO2024172932A1 (fr) * 2023-02-13 2024-08-22 Northeastern University Ligands d'endocannabinoïdes et analogues associés

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012466A1 (fr) * 1992-11-30 1994-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives d'acides gras et compositions pharmaceutiques les contenant
WO1996001558A1 (fr) * 1994-07-11 1996-01-25 Pate David W Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions
WO2001028498A2 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, ligands des recepteurs des cannabinoides presentant une affinite et une stabilite elevees

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
AU2002360436A1 (en) * 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
US20080064679A1 (en) * 2004-06-24 2008-03-13 Martin Billy R Water Soluble Cannabinoids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012466A1 (fr) * 1992-11-30 1994-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives d'acides gras et compositions pharmaceutiques les contenant
WO1996001558A1 (fr) * 1994-07-11 1996-01-25 Pate David W Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions
WO2001028498A2 (fr) * 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, ligands des recepteurs des cannabinoides presentant une affinite et une stabilite elevees

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Finding of endocannabinoids in human eye tissues: Implications for glaucoma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1016/J.BBRC.2005.03.095, vol. 330, no. 4, 20 May 2005 (2005-05-20), pages 1062 - 1067, XP004844837, ISSN: 0006-291X *
See also references of WO2007130361A1 *
WILEY J L ET AL: "Task specificity of cross-tolerance between DELTA<9>-tetrahydrocanna binol and anandamide analogs in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL LNKD- DOI:10.1016/J.EJPHAR.2005.01.006, vol. 510, no. 1-2, 7 March 2005 (2005-03-07), pages 59 - 68, XP004765702, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
AU2007248760A1 (en) 2007-11-15
WO2007130361A1 (fr) 2007-11-15
JP2009538827A (ja) 2009-11-12
EP2020850A1 (fr) 2009-02-11
CA2650900A1 (fr) 2007-11-15
CN101484004A (zh) 2009-07-15

Similar Documents

Publication Publication Date Title
HK1254895A1 (zh) 苄基苯衍生物及使用方法
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
PT2371958E (pt) Novos sirna e métodos para a sua utilização
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
EP2023718A4 (fr) Composés de ligand de créatine et procédés d&#39;utilisation correspondants
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL196462A0 (en) Substituted acylanilides and methods of use thereof
IL197185A0 (en) Substituted acylanilides and methods of use thereof
IL222947A0 (en) Luminaire and methods of use
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ZA200901842B (en) Ocular devices and methods of making and using thereof
EP2021455A4 (fr) Système de préparation de cytoblocs et procédés d&#39;utilisation associés
EP2021555A4 (fr) Élément structurel et procédés d&#39;utilisation associés
GB0719577D0 (en) Microimplant devices and methods of making and use thereof
IL206125A0 (en) Azaindolizines and methods of use
ZA200900203B (en) Adjuvants and methods of use
EP2020850A4 (fr) Nouveaux cannabinoïdes et procédés d&#39;utilisation
EP2037895A4 (fr) Trochisques à base de xilitol et leurs procédés d&#39;utilisation
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
IL192564A0 (en) Composition and method of use thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
EP2101575A4 (fr) Composés activateurs de l&#39;ace2 et procédés d&#39;utilisation de ceux-ci
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100910

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110409